Form 4: Benitec Biopharma Director Receives Stock Option Grant
Statement of Changes in Beneficial Ownership
Director David Matthew Friedman was granted 35,000 stock options as part of his board compensation at Benitec Biopharma.
Summary
- Director David Matthew Friedman received a grant of 35,000 stock options to purchase common stock in Benitec Biopharma.
- The options have an exercise price of $11.45 per share.
- The options are set to expire on May 26, 2036.
- The grant is associated with Mr. Friedman's service on the Board of Directors.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on the company's operational outlook.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
Negatives
- The grant results in potential future dilution for existing shareholders upon exercise.
Risks
- Market volatility affecting the value of the underlying common stock.
- Potential for future dilution of equity.
Future Outlook
The options vest in full on the earlier of the next annual meeting of stockholders or May 26, 2027.
Management Comments
- Mr. Friedman disclaims beneficial ownership of the options, noting they are held for the benefit of the Funds managed by Suvretta Capital Management, LLC.
Industry Context
StockSavvy.ai notes that equity-based compensation for board members is a standard practice in the biotechnology sector to ensure director retention and alignment with corporate performance milestones.
Comparison to Industry Standards
- The use of stock options for board compensation is consistent with standard governance practices for small-cap biotech firms.
- The vesting period of approximately one year is standard for annual director equity grants.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Director Compensation | Grant of 35,000 stock options to Director David Matthew Friedman. | 05/26/2026 | Standard compensation adjustment; no change to board structure. |
Related Party Transactions
- The reporting person is a Managing Director of Suvretta Capital Management, LLC, which is the investment manager for funds that may benefit from this director compensation.
Stakeholder Impact
- Minor dilution impact on existing shareholders upon potential future exercise of options.
Next Steps
- Vesting of options by May 26, 2027, or the next annual meeting.
Key Dates
| Date | Description |
|---|---|
| 05/26/2026 | Date of the option grant transaction. |
| 05/28/2026 | Date the Form 4 was signed and filed. |
| 05/26/2027 | Vesting deadline for the options. |
| 05/26/2036 | Expiration date of the options. |
Keywords
Benitec Biopharma, BNTC, Form 4, Director Compensation, Stock Options, Insider Transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.